These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5 6 7
ANJ Tutt;  JE Garber; B Kaufman; G Viale; D Fumagalli; P Rastogi; RD Gelber; M E de Azambuja; A Fielding; J Balmaña; SM Domchek; K Gelmon; SJ Hollingsworth; LA Korde; B Linderholm; H Bandos; E Senkus; JM Suga; Z Shao; AW Pippas; Z Nowecki; T Huzarski; PA Ganz; PC Lucas; N Baker; S Loibl; R McConnell; M Piccart; R Schmutzler; GG Steger; JP Costantino; A Arahmani; N Wolmark; E McFadden; V Karantza; SR Lakhani; G Yothers; C Campbell; CE Geyer Jr;  2021

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

The New England Journal of Medicine,  Published online June 03, 2021, doi:10.1056/NEJMoa2105215

M Piccart;  M Procter; D Fumagalli; E. de Azambuja; E Clark; M S Ewer; E Restuccia; G Jerusalem; S Dent; L Reaby; H Bonnefoi; I Krop; T-W Liu; T Pie?kowski; M Toi; N Wilcken; M Andersson; Y H Im; L M Tseng; H-J Lueck; M Colleoni; E Monturus; M Sicoe; S Guillaume; J Bines; RD Gelber; G Viale; C Thomssen;  2021

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up

Journal of Clinical Oncology,  Published online February 04, 2021, doi:10.1200/JCO.20.01204

E Riley;  E McFadden;  2020

Contracts and Budgets

In: Piantadosi S., Meinert C.L. (eds) Principles and Practice of Clinical Trials,  Published online November 23 2020, doi:10.1007/978-3-319-52677-5_47-1>, 

N Ponde;  D Agbor-Tarh; L D Lago; LA Korde; F Hilbers; C Jackisch; O Werner; RD Gelber; A Jatoi; AC Dueck; A Moreno-Aspitia; C Sotiriou; E. de Azambuja; M. Piccart;  2020

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

Breast Cancer Research and Treatment,  Published online 19 September 2020, doi:10.1007/s10549-020-05915-9

D Eiger;  N F Pondé; D Agbor-Tarh; A Moreno-Aspitia; M. Piccart; F Hilbers; O Werner; S Chumsri; A Dueck; J R Kroep; H Gomez; I Láng; R J Rodeheffer; M S Ewer; T Suter; E. de Azambuja;  16 March 2020

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

British Journal of Cancer,  Volume 122, pp 1453–1460(2020), doi:10.1038/s41416-020-0786-x

M Procter;  T M Suter; E. de Azambuja; U Dafni; V Van Dooren; S Muehlbauer; M Angel Climent; E Rechberger; W Tsang-Wu Liu; M Toi; R C Coombes; D Dodwell; O Pagani; J Madrid; M Hall; S Chen; C Focan; M Muscholl; D J van Veldhuisen; M Piccart-Gebhart;  2010

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

Journal of Clinical Oncology,  Volume 28 (21) pp 3422-3428, 10.1200/JCO.2009.26.0463

E McFadden;  J Jackson; J Forrest;  2019

Documentation: Essential Documents and Standard Operating Procedures

Principles and Practice of Clinical Trials,  Published online 8 November 2019, doi:10.1007/978-3-319-52677-5_45-1

J Bines;  M Procter; E Restuccia; G Viale; D Zardavas; T Suter; A Arahmani; V Van Dooren; J Baselga; E Clark; J Eng-Wong; RD Gelber; M. Piccart; V Mobus; E. de Azambuja;  2019

Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-positive breast cancer patients

Clinical Breast Cancer,  Pages 174 - 181, Volume 20 Issue 2. Published online 5 September 2019, doi:10.1016/j.clbc.2019.06.016

R Hui;  A Pearson; J Cortés; C Campbell; C Poirot; H A Azim; D Fumagalli; M Lambertini; F Daly; A Arahmani; J Pérez-Garcia; P Aftimos; P L Bedard; L Xuereb; E D Scheepers; M Vicente; T Goulioti; S Loibl; S Loi; M-J Pierrat; N C Turner; F Andre; G Curigliano;  2020

Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study

Clinical Cancer Research,  Volume 26(2), pp 354-363, doi:10.1158/1078-0432.CCR-19-1164

1 2 3 4 5 6 7